Demet Yaldız1, Arkın Acar2, Şeyda Örs Kaya2, Zekiye Aydoğdu3, Soner Gürsoy2, Sadık Yaldız1. 1. Department of Thoracic Surgery, Manisa Celal Bayar University, Faculty of Medicine, Manisa, Turkey. 2. Department of Thoracic Surgy, Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Izmir, Turkey. 3. Department of Pathology, Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Izmir, Turkey.
Abstract
BACKGROUND: This study aims to investigate whether papillary predominant histological subtype can predict poor survival in lung adenocarcinoma. METHODS: Between January 2005 and December 2016, a total of 80 patients with papillary predominant subtype lung adenocarcinoma (70 males, 10 females; mean age 60.7 years; range, 42 to 79 years) operated in our clinic were included in the study. These patients were compared with those having lepidic, acinar, and mucinous subtypes. Overall and five-year survival rates were evaluated. RESULTS: Five-year survival was 40.5% in papillary predominant histological subtype, while this rate was 70.9%, 59.0%, and 66.6% in lepidic, acinar, and mucinous subtypes, respectively. Papillary subtype showed significantly poor survival compared to lepidic (p=0.002), acinar (p=0.008), and mucinous subtypes (p=0.048). In Stage 1 disease, it was more evident (papillary, 47.5%, lepidic 86.9% [p=0.001], acinar 69.3% [p=0.040], and mucinous 90.0% [p=0.050]). CONCLUSION: Our study results suggest that papillary predominant subtype predicts poor survival in lung adenocarcinoma and these cases may be candidates for adjuvant treatment modalities even in the earlier stages of disease.
BACKGROUND: This study aims to investigate whether papillary predominant histological subtype can predict poor survival in lung adenocarcinoma. METHODS: Between January 2005 and December 2016, a total of 80 patients with papillary predominant subtype lung adenocarcinoma (70 males, 10 females; mean age 60.7 years; range, 42 to 79 years) operated in our clinic were included in the study. These patients were compared with those having lepidic, acinar, and mucinous subtypes. Overall and five-year survival rates were evaluated. RESULTS: Five-year survival was 40.5% in papillary predominant histological subtype, while this rate was 70.9%, 59.0%, and 66.6% in lepidic, acinar, and mucinous subtypes, respectively. Papillary subtype showed significantly poor survival compared to lepidic (p=0.002), acinar (p=0.008), and mucinous subtypes (p=0.048). In Stage 1 disease, it was more evident (papillary, 47.5%, lepidic 86.9% [p=0.001], acinar 69.3% [p=0.040], and mucinous 90.0% [p=0.050]). CONCLUSION: Our study results suggest that papillary predominant subtype predicts poor survival in lung adenocarcinoma and these cases may be candidates for adjuvant treatment modalities even in the earlier stages of disease.
Authors: Arne Warth; Thomas Muley; Alexander Harms; Hans Hoffmann; Hendrik Dienemann; Peter Schirmacher; Wilko Weichert Journal: Am J Surg Pathol Date: 2016-06 Impact factor: 6.394
Authors: Prudence A Russell; Zoe Wainer; Gavin M Wright; Marissa Daniels; Matthew Conron; Richard A Williams Journal: J Thorac Oncol Date: 2011-09 Impact factor: 15.609
Authors: Akihiko Yoshizawa; Noriko Motoi; Gregory J Riely; Cami S Sima; William L Gerald; Mark G Kris; Bernard J Park; Valerie W Rusch; William D Travis Journal: Mod Pathol Date: 2011-01-21 Impact factor: 7.842
Authors: Gabriel Sica; Akihiko Yoshizawa; Camelia S Sima; Christopher G Azzoli; Robert J Downey; Valerie W Rusch; William D Travis; Andre L Moreira Journal: Am J Surg Pathol Date: 2010-08 Impact factor: 6.394
Authors: Ming-Sound Tsao; Sophie Marguet; Gwénaël Le Teuff; Sylvie Lantuejoul; Frances A Shepherd; Lesley Seymour; Robert Kratzke; Stephen L Graziano; Helmut H Popper; Rafael Rosell; Jean-Yves Douillard; Thierry Le-Chevalier; Jean-Pierre Pignon; Jean-Charles Soria; Elisabeth M Brambilla Journal: J Clin Oncol Date: 2015-04-27 Impact factor: 44.544
Authors: Jan H von der Thüsen; Yuen S Tham; Holly Pattenden; Alexandra Rice; Michael Dusmet; Eric Lim; Andrew G Nicholson Journal: J Thorac Oncol Date: 2013-01 Impact factor: 15.609